Mycophenolate mofetil: An update

Drugs of Today

Volumn 45, Issue 7, 2009, Pages 521-532

  Villarroel, Maria Cristina ^a   Hidalgo, Manuel ^a   Jimeno, Antonio ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; EVEROLIMUS; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ANTIANGIOGENIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIGEN PRESENTATION; ANTIPROTOZOAL ACTIVITY; AREA UNDER THE CURVE; CARDIAC GRAFT REJECTION; DENDRITIC CELL; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENTEROHEPATIC CIRCULATION; GLOMERULONEPHRITIS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNE COMPLEX NEPHRITIS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEISHMANIA TROPICA; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PANCREAS TRANSPLANTATION; PNEUMOCYSTIS CARINII; POSTOPERATIVE COMPLICATION; PSORIASIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; PRODRUGS;

EID: 71249141502     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.7.1384878     Document Type: Review

References (113)

1. Birkinshaw, J.H., Raistrick, H., Ross, D.J. Studies in the biochemistry of micro-organisms. 86. The molecular constitution of mycophenolic acid, a metabolic product of Penicillium Brevi-compactum Dierckx. Part III. Further observations on the structural formula for mycophenolic acid. Biochem J 1952, 50(5): 630-634
2. Abraham, E.P. The effect of mycophenolic acid on the growth of Staphylococcus aureus in heart broth. Biochem J 1945, 39(5): 398-408.
3. Sweeney, M.J., Gerzon, K., Harris, P.N., Holmes, R.E., Poore, G.A., Williams, R.H. Experimental antitumor activity and preclinical toxicology of mycophenolic acid. Cancer Res 1972, 32(9): 1795-1802
4. Franklin, T.J., Cook, J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969, 113(3): 515-524
5. Allison, A.C., Hovi, T., Watts, R.W., Webster, A.D. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 1975, 2(7946): 1179-1183
6. Nelson, P.H., Eugui, E., Wang, C.C., Allison, A.C. Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Med Chem 1990, 33(2): 833-838 (Pubitemid 20047615)
7. Eugui, E.M., Almquist, S.J., Muller, C.D., Allison, A.C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991, 33(2): 161-173
8. Sintchak, M.D., Nimmesgern, E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000, 47(2-3): 163-184 (Pubitemid 30394537)
9. Garcia, R.C., Leoni, P., Allison, A.C. Control of phosphoribosylpyrophosphate synthesis in human lymphocytes. Biochem Biophys Res Commun 1977, 77(3): 1067-1073 (Pubitemid 8157469)
10. Platz, K.P., Bechstein, W.O., Eckhoff, D.E., Suzuki, Y., Sollinger, H.W. RS-61443 reverses acute allograft rejection in dogs. Surgery 1991, 110(4): 736-740
11. Allison, A.C., Eugui, E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47(2-3): 85-118.
12. Balendiran, G.K., Molina, J.A., Xu, Y. et al. Ternary complex structure of human HGPRTase, PRPP, Mg2+, and the inhibitor HPP reveals the involvement of the flexible loop in substrate binding. Protein Sci 1999, 8(5): 1023-1031 (Pubitemid 29211740)
13. Nakamura, M., Ogawa, N., Shalabi, A., Maley. W.R., Longo, D., Burdick, J.F. Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil. Clin Transplant 2001, 15(Suppl 6): 36-40. (Pubitemid 33062044)
14. Quemeneur, L., Flacher, M., Gerland, L.M., Ffrench, M., Revillard, J.P., Bonnefoy-Berard, N. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002, 169(5): 2747-2755 (Pubitemid 34921024)
15. Eugui, E.M., Mirkovich, A., Allison, A,C. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991, 33(2): 175-183
16. Grailer, A., Nichols, J., Hullett, D., Sollinger, H.W., Burlingham, W.J. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 IL-2. Transplant Proc 1991, 23(1 Pt 1): 314-315
17. Mehling, A., Grabbe, S., Voskort, M., Schwarz, T., Luger, T.A., Beissert, S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000, 165(5): 2374-2381 (Pubitemid 30660679)
18. Haug, C., Schmid-Kotsas, A., Linder, T. et al. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci (Lond) 2002, 103(Suppl. 48): 76S-80S. (Pubitemid 35007125)
19. Bullingham, R., Monroe, S., Nicholls, A., Hale, M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996, 36(4): 315-324 (Pubitemid 26125953)
20. Parker, G., Bullingham, R., Kamm, B., Hale, M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996, 36(4): 332-344 (Pubitemid 26125954)
21. Bullingham, R.E., Nicholls, A.J., Kamm, B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34(6): 429-455 (Pubitemid 28273453)
22. Sweeney, M.J. Mycophenolic acid and its mechanism of action in cancer and psoriasis. Jpn J Antibiot 1977, 30(Suppl.): 85-92.
23. Shaw, L.M., Korecka, M., Venkataramanan, R., Goldberg, L., Bloom, R., Brayman, K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003, 3(5): 534-542 (Pubitemid 36612836)
24. Nowak, I., Shaw, L.M. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics. Clin Chem 1995, 41(7): 1011-1017
25. Kaplan, B., Meier-Kriesche, H.U., Friedman, G. et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999, 39(7): 715-720
26. Kiberd, B.A., Puthenparumpil, J.J., Fraser, A., Tett, S.E., Lawen, J. Impact of mycophenolate mofetil loading on drug exposure in the early posttransplant period. Transplant Proc 2005, 37(5): 2320-2323 (Pubitemid 40956441)
27. Buchler, M., Lebranchu, Y., Beneton, M. et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 2005, 78(1): 34-42. (Pubitemid 40956929)
28. Atcheson, B.A., Taylor, P.J., Kirkpatrick, C.M. et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004, 26(3): 284-286 (Pubitemid 38703015)
29. Cox, V.C., Ensom, M.H. Mycophenolate mofetil for solid organ transplantation: Does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003, 25(2): 137-157
30. Berman, J.D., Webster, H.K. In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages. Antimicrob Agents Chemother 1982, 21(6): 887-891
31. O'Gara, M.J., Lee, C.H., Weinberg, G.A., Nott, J.M., Queener, S.F. IMP dehydrogenase from Pneumocystis carinii as a potential drug target. Antimicrob Agents Chemother 1997, 41(1): 40-48
32. Oz, H.S., Hughes, W.T. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997, 175(4): 901-904
33. Wu, X., Zhong, H., Song, J., Damoiseaux, R., Yang, Z., Lin, S. Mycophenolic acid is a potent inhibitor of angiogenesis. Arterioscler Thromb Vasc Biol 2006, 26(10): 2414-2416 (Pubitemid 44465742)
34. Chong, C.R., Qian, D.Z., Pan, F. et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006, 49(9): 2677-2680
35. Koehl, G.E., Wagner, F., Stoeltzing, O. et al. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 2007, 83(5): 607-614 (Pubitemid 46440251)
36. Domhan, S., Muschal, S., Schwager, C. et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008, 7(6): 1656-1668
37. Platz, K.P., Sollinger, H.W., Hullett, D.A., Eckhoff, D.E., Eugui, E.M., Allison, A.C. RS-61443 - A new, potent immunosuppressive agent. Transplantation 1991, 51(1): 27-31.
38. Sollinger, H.W., Belzer, F.O., Deierhoi, M.H. et al. RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 1992, 216(4): 513-8; discussion 8-9.
39. Deierhoi, M.H., Kauffman, R.S., Hudson, S.L. et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 1993, 217(5): 476-482
40. Sollinger, H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60(3): 225-232
41. Halloran, P., Mathew, T., Tomlanovich, S., Groth, C., Hooftman, L., Barker, C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997, 63(1): 39-47. (Pubitemid 27036687)
42. Vanrenterghem, Y. The use of mycophenolate mofetil (Cellcept) in renal transplantation. Nephron 1997, 76(4): 392-399 (Pubitemid 27353181)
43. Simmons, W.D., Rayhill, S.C., Sollinger, H.W. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997, 17(2): 75-92.
44. Tedesco-Silva, H., Szakaly, P., Shoker, A. et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: Six-month results of a double-blind study. Transplantation 2007, 84(7): 885-892 (Pubitemid 351338950)
45. Vitko, S., Margreiter, R., Weimar, W. et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005, 5(10): 2521-2530 (Pubitemid 43919438)
46. Buchler, M., Caillard, S., Barbier, S. et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007, 7(11): 2522-2531 (Pubitemid 47561618)
47. Roth, D., Colona, J., Burke, G.W., Ciancio, G., Esquenazi, V., Miller, J. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998, 65(2): 248-252 (Pubitemid 28099219)
48. Shapiro, R., Jordan, M.L., Scantlebury, V.P. et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/ mycophenolate mofetil in renal transplant recipients. Transplantation 1999, 67(3): 411-415 (Pubitemid 29094012)
49. Wiesel, M., Carl, S. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group. J Urol 1998, 159(1): 28-33.
50. Gonwa, T., Johnson, C., Ahsan, N. et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003, 75(12): 2048-2053 (Pubitemid 36793291)
51. Ekberg, H., Tedesco-Silva, H., Demirbas, A. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357(25): 2562-2575 (Pubitemid 350294223)
52. Sola, R., Guirado, L., Diaz, J.M. et al. Tacrolimus/mycophenolate mofetil-based immunosuppression in aged kidney transplant. A prospective study. Int Immunopharmacol 2005, 5(1): 129-131 (Pubitemid 39626695)
53. Arbogast, H., Huckelheim, H., Schneeberger, H. et al. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: Long-term results from a prospective single centre trial. Clin Transplant 2005, 19(3): 309-315 (Pubitemid 40711962)
54. Kobashigawa, J.A. Mycophenolate mofetil in cardiac transplantation. Curr Opin Cardiol 1998, 13(2): 117-121
55. Kobashigawa, J., Miller, L., Renlund, D. et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998, 66(4): 507-515 (Pubitemid 28415379)
56. Hosenpud, J.D., Bennett, L.E. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: An analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001, 72(10): 1662-1665
57. Hamour, I.M., Lyster, H.S., Burke, M.M., Rose, M.L., Banner, N.R. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients. Transplantation 2007, 83(5): 570-576
58. Groetzner, J., Kaczmarek, I., Landwehr, P. et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004, 25(3): 333-341 (Pubitemid 38340566)
59. Angermann, C.E., Stork, S., Costard-Jackle, A. et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients - the IMPROVED multi-centre study. Eur Heart J 2004, 25(18): 1626-1634 (Pubitemid 39209283)
60. Kobashigawa, J.A., Miller, L.W., Russell, S.D. et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, 6(6): 1377-1386 (Pubitemid 44030320)
61. Mastrobuoni, S., Ubilla, M., Cordero, A., Herreros, J., Rabago, G. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: Early experience. Transplant Proc 2007, 39(7): 2163-2166 (Pubitemid 47418179)
62. Pethig, K., Heublein, B., Wahlers, T., Dannenberg, O., Oppelt, P., Haverich, A. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: Influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 2004, 23(1): 61-66 (Pubitemid 38088020)
63. El-Sayed, O., Magorien, R.D., Orsini, A., Ferketich, A.K., Leier, C.V. Advancing immunosuppression therapy to counter the progression of cardiac allograft vasculopathy. J Card Fail 2005, 11(2): 137-141 (Pubitemid 40269790)
64. Li, H., Tanaka, K., Chhabra, A., Oeser, B., Kobashigawa, J.A., Tobis, J.M. Vascular remodeling 1 year after cardiac transplantation. J Heart Lung Transplant 2007, 26(1): 56-62. (Pubitemid 46096747)
65. McDiarmid, S.V. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996, 10(1 Pt 2): 140-145
66. Eckhoff, D.E., McGuire, B.M., Frenette, L.R., Contreras, J.L., Hudson, S.L., Bynon, J.S. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998, 65(2): 180-187
67. Schlitt, H.J., Barkmann, A., Boker, K.H. et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001, 357(9256): 587-591 (Pubitemid 32179611)
68. Koch, R.O., Graziadei, I.W., Schulz, F. et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004, 17(9): 518-524 (Pubitemid 39592738)
69. Stewart, S.F., Hudson, M., Talbot, D., Manas, D., Day, C.P. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001, 357(9256): 609-610 (Pubitemid 32179620)
70. Cantarovich, M., Tzimas, G.N., Barkun, J., Deschenes, M., Alpert, E., Tchervenkov, J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003, 76(1): 98-102. (Pubitemid 36877122)
71. Pageaux, G.P., Rostaing, L., Calmus, Y. et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006, 12(12): 1755-1760 (Pubitemid 44920019)
72. Moreno, J.M., Rubio, E., Gomez, A. et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003, 35(5): 1874-1876 (Pubitemid 37093747)
73. Schuller, S., Wiederkehr, J.C., Coelho-Lemos, I.M., Avilla, S.G., Schultz, C. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. Transplant Proc 2005, 37(2): 1151-1152 (Pubitemid 40590820)
74. Figueras, J., Prieto, M., Bernardos, A. et al. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 2006, 19(8): 641-648
75. Jain, A., Kashyap, R., Demetris, A.J., Eghstesad, B., Pokharna, R., Fung, J.J. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002, 8(1): 40-46 (Pubitemid 34092671)
76. Firpi, R.J., Nelson, D.R., Davis, G.L. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 2003, 9(1): 57-61.
77. Kornberg, A., Kupper, B., Tannapfel, A., Hommann, M., Scheele, J. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol 2005, 5(1): 107-115 (Pubitemid 39626692)
78. Klintmalm, G.B., Washburn, W.K., Rudich, S.M. et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007, 13(11): 1521-1531
79. Lee, C.M., Scandling, J.D., Krieger, N.R., Dafoe, D.C., Alfrey, E.J. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. Transplantation 1997, 64(9): 1288-1294
80. Stegall, M.D., Simon, M., Wachs, M.E., Chan, L., Nolan, C., Kam, I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 1997, 64(12): 1695-1700 (Pubitemid 28041702)
81. Merion, R.M., Henry, M.L., Melzer, J.S., Sollinger, H.W., Sutherland, D.E., Taylor, R.J. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 2000, 70(1): 105-111 (Pubitemid 30490760)
82. Hesse, U.J., Troisi, R., Jacobs, B. et al. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin Transplant 2000, 14(4 Pt 1): 340-344 (Pubitemid 30497138)
83. Ciancio, G., Lo Monte, A., Buscemi, G., Miller, J., Burke, G.W. Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation. Transpl Int 2000, 13(Suppl. 1): S191-4.
84. Malaise, J., Kuypers, D.R., Claes, K. et al. Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. Transplant Proc 2005, 37(6): 2840-2842 (Pubitemid 41354751)
85. Ross, D.J., Waters, P.F., Levine, M., Kramer, M., Ruzevich, S., Kass, R.M. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: Preliminary experience. J Heart Lung Transplant 1998, 17(8): 768-774 (Pubitemid 28396986)
86. O'Hair, D.P., Cantu, E., McGregor, C. et al. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant 1998, 17(9): 864-868 (Pubitemid 28440847)
87. Zuckermann, A., Klepetko, W., Birsan, T. et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999, 18(5): 432-440 (Pubitemid 29256353)
88. Chan, T.M., Li ,FK.,. Tang, C.S. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343(16): 1156-1162
89. Hu, W., Liu, C., Xie, H., Chen, H., Liu, Z., Li, L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008, 23(4): 1307-1312 (Pubitemid 351767500)
90. Kingdon, E.J., McLean, A.G., Psimenou, E. et al. The safety and efficacy of MMF in lupus nephritis: A pilot study. Lupus 2001, 10(9): 606-611 (Pubitemid 32959274)
91. Chan, T.M., Tse, K.C., Tang, C.S., Mok, M.Y., Li, F.K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16(4):1076-1084
92. Ginzler, E.M., Aranow, C. Mycophenolate mofetil in lupus nephritis. Lupus 2005, 14(1): 59-64.
93. Moore, R.A., Derry, S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006, 8(6): R182. (Pubitemid 46306295)
94. Zhu, B., Chen, N., Lin, Y. et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007, 22(7): 1933-1942 (Pubitemid 47244763)
95. Schanz, S., Ulmer, A., Rassner, G., Fierlbeck, G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002, 147(1): 174-178 (Pubitemid 34779458)
96. Hanjani, N.M, Nousari, C.H. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002, 138(12): 1616-1618 (Pubitemid 35453486)
97. Boehm, I., Bieber, T. Chilblain lupus erythematosus Hutchinson: Successful treatment with mycophenolate mofetil. Arch Dermatol 2001, 137(2): 235-236 (Pubitemid 32163685)
98. Goyal, S., Nousari, H.C. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001, 45(1): 142-144 (Pubitemid 32655712)
99. Pisoni, C.N., Obermoser, G., Cuadrado, M.J. et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: Poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005, 23(3): 393-396 (Pubitemid 40823550)
100. Choi, M.J., Eustace, J.A., Gimenez, L.F. et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002, 61(3): 1098-1114 (Pubitemid 34175479)
101. Segarra, A., Amoedo, M.L., Martinez Garcia, J.M. et al. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis - a multicenter study. Nephrol Dial Transplant 2007, 22(5): 1351-1360
102. Dimitrakov, D.J., Nikolov, D.G., Dimitrakov, J.D. et al. Effect of mycophenolate mofetil (CellCept) in the treatment of immune glomerulopathies. Folia Med (Plovdiv) 2004, 46(1): 15-18
103. Maes, B.D., Oyen, R., Claes, K. et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004, 65(5): 1842-1849 (Pubitemid 38591034)
104. Frisch, G., Lin, J., Rosenstock, J. et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 2005, 20(10): 2139-2145 (Pubitemid 41510089)
105. Tang, S., Leung, J.C., Chan, L.Y. et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005, 68(2): 802-812 (Pubitemid 43323137)
106. Jones, E.L., Epinette, W.W., Hackney, V.C., Menendez, L., Frost, P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975, 65(6): 537-542
107. Marinari, R., Fleischmajer, R., Schragger, A.H, Rosenthal, A.L. Mycophenolic acid in the treatment of psoriasis: Long-term administration. Arch Dermatol 1977, 113(7): 930-932 (Pubitemid 8146834)
108. Spatz, S., Rudnicka, A., McDonald, C.J. Mycophenolic acid in psoriasis. Br J Dermatol 1978, 98(4): 429-435
109. Gomez, E.C., Menendez, L., Frost, P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1979, 1(6): 531-537
110. Davison, S.C., Morris-Jones, R., Powles, A.V., Fry, L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000, 143(2): 405-407 (Pubitemid 30650413)
111. Pedraz, J., Dauden, E., Delgado-Jimenez, Y., Garcia-Rio, I., Garcia-Diez, A. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin. J Eur Acad Dermatol Venereol 2006, 20(6): 702-706 (Pubitemid 43919133)
112. Enk, A.H., Knop, J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999, 135(1): 54-56 (Pubitemid 29069517)
113. Mimouni, D., Anhalt, G.J., Cummins, D.L., Kouba, D.J., Thorne, J.E., Nousari, H.C. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003, 139(6): 739-742 (Pubitemid 36705940)